Why We Lose Energy and Motivation in Depression- Insight from Dr. Rezaul Hamid I Viatris CME Lecture скачать в хорошем качестве

Why We Lose Energy and Motivation in Depression- Insight from Dr. Rezaul Hamid I Viatris CME Lecture

🧠 Energy, Motivation & Interest (EMI) in Depression | Dr. Rezaul Hamid | Viatris CME Webinar Depression is more than sadness — it disrupts energy, motivation, and interest (EMI), the neurobiological core of purposeful life. In this academic webinar, Dr. Rezaul Hamid, Psychiatrist and Founder-Director of Mindcare Neuro Psychiatry Research Centre (Assam), examines how dopamine, serotonin, and noradrenaline circuits explain residual symptoms, anhedonia, and recovery patterns. This Viatris-supported CME session highlights: • Dopaminergic dysfunction in residual symptoms • EMI as a marker for remission and functional recovery • Translational insights on Sertraline and other antidepressants • The shift from symptom control to functional restoration 🎥 Professionally recorded and edited for continuing medical education. Ideal for psychiatrists, psychologists, and mental-health clinicians seeking evidence-based understanding of depression’s circuitry and treatment advances. The video is edited in Filmora Professional and music track Automn’s Evening taken from Filmore Copyright free archive. No copyright infringement intended #Depression #Sertraline #Psychiatry #MentalHealth #Neuroscience #DrRezaulHamid #Mindcare #Viatris #Psychopharmacology #Anhedonia #Motivation #cme ________________________________________ 📚 References (as cited) 1. Schloesser RJ et al. Neuropsychopharmacology. 2008; 33:110–133. 2. Yang R et al. BioMed Res Int. 2014; 2014:915026. 3. Kupfer DJ. J Clin Psychiatry. 1991; 52:28–34. 4. Rush JA et al. Neuropsychopharmacology. 2006; 31:1841–1853. 5. Stahl SM. Essential Psychopharmacology. Cambridge Univ Press; 2000 & 2008. 6. Thase ME et al. Int Clin Psychopharmacol. 2016; 31(6):332. 7. Grace AA. Nat Rev Neurosci. 2016; 17(8):524–532. 8. Dunlop BW, Nemeroff CB. Arch Gen Psychiatry. 2007; 64(3):327–337. 9. Kitaichi Y et al. Eur J Pharmacol. 2010; 647(1):90–96. 10. Zajecka JM. J Clin Psychiatry. 2013; 74(Suppl 2):9–13. 11. Israel JA. Pharmaceuticals. 2010; 3(8):2426–2440. 12. Kennedy SH. Dialogues Clin Neurosci. 2008; 10(3):271–277. 13. Romera I et al. BMC Psychiatry. 2013; 13:51. 14. Treadway MT, Zald DH. Neurosci Biobehav Rev. 2011; 35(3):537–555. 15. Paykel ES. Dialogues Clin Neurosci. 2008; 10(4):431–437. 16. Gelenberg AJ. APA Practice Guideline for MDD (3rd ed). 2010. 17. Kennedy SH et al. J Affect Disord. 2009; 117:S1–S2. 18. Korte SM et al. Eur J Pharmacol. 2015; 753:88–104. 19. Nestler EJ, Carlezon WA. Biol Psychiatry. 2006; 59(12):1151–1159. 20. Ciraulo DA et al. In: Pharmacotherapy of Depression. Humana Press; 2004. 21. Fabre LF et al. Biol Psychiatry. 1995; 38(9):592–602. 22. Lepine JP et al. Am J Psychiatry. 2004; 161:836–842. 23. Sanchez C et al. Int Clin Psychopharmacol. 2014; 29(4):185–196. 24. Bergeron R et al. Eur J Pharmacol. 1993; 240:319–323. 25. Boyer P et al. J Clin Pharm Ther. 2000; 25(5):363–371. 26. Keller MB et al. JAMA. 1998; 280(19):1665–1672. 27. MacQueen G et al. CNS Drug Rev. 2001; 7(1):1–24. 28. Orzechowska A et al. Med Sci Monit. 2015; 21:3643–3651. 29. Inoue T et al. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(2):223–227. 30. Nasr S, Wendt B. Int J Psychiatry Clin Pract. 2006; 10(4):297–299. 31. Sherwood A et al. Psychosom Med. 2016; 78:602–609. 32. Krishnan KRR et al. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25:347–361. 33. Matrisciano F et al. J Psychiatr Res. 2009; 43(3):247–254. 34. Lippincott Williams & Wilkins Atlas of Anatomy. 2008. ________________________________________ #Depression #Sertraline #Psychiatry #MentalHealth #Neuroscience #DrRezaulHamid #Mindcare #Viatris #Psychopharmacology #Anhedonia #Motivation #CME #Neurobiology